Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
OTC Drugs

GSK Divests Non-Core OTCs To Focus On "Priority Brands," Emerging Markets

This article was originally published in The Tan Sheet

  • News

Executive Summary

GlaxoSmithKline will divest non-core OTC products to accelerate consumer health care growth and help fund a share buy-back program following a financial wipeout in the firm's most recent quarter.

You may also be interested in...



Central, Eastern Europe Lead OTC Growth On Sector's Top Continent

Central and Eastern Europe continue to drive OTC sales growth on the continent, with even low-growth countries matching the best levels in Western Europe

Central, Eastern Europe Lead OTC Growth On Sector’s Top Continent

Central and Eastern Europe continue to drive OTC sales growth on the continent, with even low-growth countries matching the best levels in Western Europe.

Central, Eastern Europe Lead OTC Growth On Sector’s Top Continent

Central and Eastern Europe continue to drive OTC sales growth on the continent, with even low-growth countries matching the best levels in Western Europe.

Table

View full table

Related Content

Pink Sheet
HBW Insight
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
OTC Drugs
Latest Headlines

Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation

Pink Sheet Podcast: US FDA Loses Gene Therapy Expert, Humira Biosimilars Launch, FDA Allows In-Person Meetings

Recent And Upcoming FDA Advisory Committee Meetings

EU CHMP Opinions and MAA Updates

See All
UsernamePublicRestriction

Register

PS104842

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By